1 November 2016 - NICE has issued draft guidance on the use of Taltz (ixekizumab) for the treatment of patients with moderate/severe plaque psoriasis.

Ixekizumab is recommended as an option for treating plaque psoriasis in adults, only if:

• the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index of more than 10
  
• the disease has not responded to standard systemic therapies, for example, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or the person cannot have the treatment or it is not tolerated and
  
• the company provides ixekizumab with the discount agreed in the patient access scheme.
  

Final guidance is expected in April 2017.

Read NICE draft guidance for ixekizumab